Around a third of people with major depressive disorder don't respond to standard treatments – but an alternative therapy may be hiding right under our noses. As strange as it sounds, a new approach targeting inflammation could help. Tocilizumab is an anti-inflammatory drug commonly used to treat immune conditions such as rheumatoid arthritis – and it may help patients whose depression does not respond to standard treatments. Across a four-week, proof-of-concept trial, 30 people with moderate-